NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
02/01/2020
Back to search
Official data from USPTO
ETHYPHARM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ETHYPHARM
ST13
US500000077453036Class
5, 42
Filing
77453036
Registration
3641981
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
04/07/2023
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
04/21/2008
Registration date
06/23/2009
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/01/2020
Last transaction
04/07/2023
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
1999-07-00
First use in commerce
1999-07-00
Drawing code
4
Owner type
99
Owner location
Saint Cloud, FR
Examiner
BENJAMIN, SARA NICOLE
Law office
M10
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Ethypharm, S.A.
Ethypharm, S.A.
Representatives
CATHLEEN E. STADECKER, DOWNS RACHLIN MARTIN PLLC
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productspreparations and substancespain relieversanti-inflammatoriesanti-infection agentsanti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditionsrespiratory conditionsgastrointestinal conditionshyper-cholesterolemiagenitourinary conditionsvomitingallergiesdegenerative diseases and central nervous system diseases; excipientsdrug delivery agents consisting of compounds that facilitate the delivery a wide range of pharmaceuticals; veterinary pharmaceutical productspreparations and substancespain relieversanti-inflammatoriesanti-infection agentsanti-cancer treatments and anti-addiction agents all for the treatment of cardiovascular conditionsrespiratory conditionsgastrointestinal conditionshyper-cholesterolemiagenitourinary conditionsvomitingallergiesdegenerative diseases and central nervous system diseases; sanitary pharmaceutical products for medical purposespain relieversanti-inflammatoriesanti-infection agentsanti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditionsrespiratory conditionsgastrointestinal conditionshyper-cholesterolemia genitourinary conditionsvomitingallergiesdegenerative disease and central nervous system diseases; dietetic substances adopted for medical use; all purpose disinfectants; chemicalbiological and biochemical pharmaceutical products for medical and veterinary usepain relieversanti-inflammatoriesanti-infection agentsanti-cancer treatments and anti-addiction agents for the treatment of cardiovascular conditionsrespiratory conditionsgastrointestinal conditionshyper-cholesterolemia genitourinary conditionsvomitingallergiesdegenerative disease and central nervous system diseases
Class 42
Medical studies and clinical studiesscientific research services for medical purposes; research and development of new products for third parties in the medical and pharmaceutical field; engineering services in the medical and pharmaceutical field; chemical research; chemical analyses
Publications
History of USPTO decisions and trademark events.
39 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
02/01/2020
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
02/01/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/01/2020
E89R
TEAS SECTION 8 & 9 RECEIVED
12/18/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/23/2018
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
11/03/2016
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
11/03/2016
ES7R
TEAS SECTION 7 REQUEST RECEIVED
11/02/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
10/27/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/27/2016
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/26/2016
REIN
REINSTATED
10/26/2016
C8..
CANCELLED SEC. 8 (6-YR)
10/04/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
03/04/2016
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
07/17/2015
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/16/2015
E815
TEAS SECTION 8 & 15 RECEIVED
06/23/2015
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS NOT UPDATED
09/25/2012
PAPER RECEIVED
09/13/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
06/23/2009
PUBO
PUBLISHED FOR OPPOSITION
04/07/2009
NPUB
NOTICE OF PUBLICATION
03/18/2009
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/02/2009
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/27/2009
XAEC
EXAMINER'S AMENDMENT ENTERED
02/27/2009
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/27/2009
GNEA
EXAMINERS AMENDMENT E-MAILED
02/27/2009
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/27/2009
ACEC
AMENDMENT FROM APPLICANT ENTERED
02/05/2009
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/05/2009
ALIE
ASSIGNED TO LIE
02/05/2009
PAPER RECEIVED
02/03/2009
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/06/2008
GNRT
NON-FINAL ACTION E-MAILED
08/06/2008
CNRT
NON-FINAL ACTION WRITTEN
08/06/2008
DOCK
ASSIGNED TO EXAMINER
08/05/2008
MPMK
NOTICE OF PSEUDO MARK MAILED
04/25/2008
NWAP
NEW APPLICATION ENTERED
04/24/2008
Continuous trademark protection
Get notified about every new filing that threatens ETHYPHARM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.